DEVELOPING TOMORROW’S CANCER THERAPIES. TODAY.
- Private – spin-out from APEIRON Biologics AG
- Launched in January 2022
- Highly experienced management team with strong scientific and capital markets expertise
- In-house acumen in discovery, development, clinical trials, CMC and finance
- Seeking funding through equity investment and or partnering
Investment case: Excellent basis for future value growth
- Unencumbered focus on discovery and development of innovative cancer immunotherapies
- Proprietary cell-therapy platform enabling out-patient treatment of hard-to-access solid tumors
- Individualised, patient-centric approach
- Shown to be safe and well-tolerated in clinical trials
- Lead candidate expected to enter Phase 2 in 2024
- Complementary, high-potential orally available small molecule for tumor-specific immune activation and tumor-cell killing
- In-house innovation hub driving long-term pipeline growth
Innovative immuno-oncology pipeline
Why we target Cbl-b
-
Modulating Cbl-b is central to fighting tumor cells in a broad range of tumor indications
-
Cbl-b is involved in several negative regulatory pathways
-
Cbl-b deficiency activates a variety of immune cells for tumor destruction
For further information, please visit our main website:
Innovative immuno-oncology pipeline
Why we target Cbl-b
-
Modulating Cbl-b is central to fighting tumor cells in a broad range of tumor indications
-
Cbl-b is involved in several negative regulatory pathways
-
Cbl-b deficiency activates a variety of immune cells for tumor destruction
For further information, please visit our main website:
